Chugai Pharmaceutical Co., Ltd. · TSE:4519
Chugai Pharmaceutical — Q2 2014 Earnings Presentation
27 slides from Chugai Pharmaceutical's earnings presentation, Jul 24, 2014
Slide 1: FY2014 2Q Consolidated Financial Overview (IFRS based)
FY2014 2Q Consolidated C lid t d Financial Fi i l Overview O i (IFRS based) CHUGAI PHARMACEUTICAL CO., LTD. E Executive ti Vice Vi P President id t CFO Yoshio Itaya July 24/25, 2014
Slide 2: Forward Looking Statements
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 2Q Consolidated Financial Overview Forward Looking Statements Forward-Looking This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co.
Slide 3: Summary
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 2Q Consolidated Financial Overview Summary Revenues: 222.0 billion JPY (+10.4% YoY) • Domestic sales excl. Tamiflu (+8.8%): increase due to steady growth of mainstay products and new products • Overseas
Slide 4: IFRS and Core Results Jan – Jun
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 2Q Consolidated Financial Overview IFRS and Core Results Jan – Jun IFRS results Non-core items Core results 2014 Intangible assets Other 2014 (Billion JPY) Non-Core items and Business eliminated Jan - Jun
Slide 5: Financial Overview Jan – Jun
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 2Q Consolidated Financial Overview Year on Year (Core) Financial Overview Jan – Jun 2013 2014 ((Billion JPY)) Jan - Jun Jan - Jun Growth (Billion JPY) vs. Rev*. vs. Rev*. Revenues 201.0 222.0 +21.0 +10.4%
Slide 6: Sales (excl. Tamiflu) Jan – Jun
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 2Q Consolidated Financial Overview Year on Year Sales (excl (excl. Tamiflu) Jan – Jun Sales excl. Tamiflu (Billion JPY) 201.0 (+21.2, +11.8%) Actemra -1.9 Epogin (overseas) +8.0 179 8 179.8 Overseas (3.3)
Slide 7: Tamiflu Sales Performance
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 2Q Consolidated Financial Overview Tamiflu Sales Performance Fiscal Term Sales Forecast ((Billion JPY)) FY2009.12 FY2010.12 FY2011.12 FY2012.12 FY2013.12 FY2014.12 Cases per Seasonal sentinel* Jan-Jun Jul
Slide 8: Operating Profit Jan – Jun
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 2Q Consolidated Financial Overview Year on Year (Core) Operating Profit Jan – Jun (Billion JPY) 2013 2014 (Billion JPY) Growth Jan - Jun Jan - Jun Royalties and other M&D Revenues 201.0 222.0 +21.0 operat
Slide 9: Financial Overview Apr – Jun
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 2Q Consolidated Financial Overview Year on Year (Core) Financial Overview Apr – Jun 2013 2014 ((Billion JPY)) Apr p - Jun Apr p - Jun Growth (Billion JPY) vs. Rev*. vs. Rev*. Revenues 110.6 98.0 -12.6 -11
Slide 10: Financial Overview Jan – Jun vs. Forecast
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 2Q Consolidated Financial Overview vs. Forecast (Core) Financial Overview Jan – Jun Actual Forecast on Jan 30 2013 (Billion JPY) 2014 2014 Progress Progress* Jan - Jun Jan - Dec Revenues 222.0 451.0 49.2%
Slide 11: Domestic Sales (excl. Tamiflu) Jan – Jun
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 2Q Consolidated Financial Overview vs. Forecast (Core) Domestic Sales (excl (excl. Tamiflu) Jan – Jun Actual Forecast on Jan 30 2013 (Billion JPY) 2014 2014 Progress Progress* Jan - Jun Jan - Dec Domestic
Slide 12: Impact from Foreign Exchange
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 2Q Consolidated Financial Overview vs. Forecast (Core) Impact from Foreign Exchange Reference Assumption Jan - Dec FX rate to the JPY* Actual Jan - Jun avg. Actual Jan - Jun avg. (as of Jan. 30) (2013) 1C
Slide 13: Balance Sheet Items
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 2Q Consolidated Financial Overview vs. 2013 Year End Balance Sheet Items < Assets, Liabilities, and Net Assets > Net working capital +7.3 2013 2014 Trade accounts receivable -4.5 45 (Billion JPY) Change D
Slide 14: Net Cash
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 2Q Consolidated Financial Overview vs. 2013 Year End Net Cash Total increase in net (Billion JPY) working capital Operating cash flow after adjustments +51.9 -5.6 Total investment Operating profit +43.1 -
Slide 15: Free Cash Flow Jan - Jun
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 2Q Consolidated Financial Overview Year on Year Free Cash Flow Jan - Jun 2013 2014 Operating profit, net of operating cash (Billion JPY) Jan-Jun Jan-Jun Change adjustments +4.7 Operating profit - IFRS bas
Slide 16: Overview of Development Pipeline
Aiming to become “Top Pharmaceutical Company” O Overview i off Development D l t Pipeline Pi li CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President Head of Project & Lifecycle Management Unit Yutaka Tanaka July 24/25, 2014
Slide 17: Oncology Field Projects under Development
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline Oncology Field Projects under Development (as of 24 July, 2014) Phase I Phase II Phase III Filed CKI27 / RG7304 GC33 / RG7686 RG1273 / Perjeta RG7204 / vemurafenib (Japan / overs
Slide 18: Primary Field Projects under Development
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline Primary Field Projects under Development (as of 24 July, 2014) Phase I Phase II Phase III Filed Bone RG484 / Bonviva (oral) - osteoporosis & NRD101 / Suvenyl Joint - enthesopathy
Slide 19: Development Status: Oncology, Bone & Joint
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline D Development l t Status: St t Oncology, O l Bone B & Joint J i t In- In AF802 / Alecensa ® : house ALK fusion gene positive unresectable, recurrent / advanced non- small cell lu
Slide 20: Development Status: Autoimmune Diseases
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline D Development l t St Status: t Autoimmune A t i Diseases Di In- MRA / Actemra ® : house New formulation (subcutaneous injection) for RA April 2014: Approved in EU June 2014: Star
Slide 21: Development Status: CNS, Others
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline D Development l t St Status: t CNS, CNS Others Oth CNS: Central Nervous System In- RG1662 (GABAAα5 receptor antagonist ) : licensed Improvement of intellectual ability in individ
Slide 22: Other Progress: Data Presentation
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline Oth Progress: Other P Data D t Presentation P t ti Data presentation at scientific meetings In- World Federation of Hemophilia 2014 (May) house ACE910: presented preliminary da
Slide 23: Other Progress: License in Europe
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline Oth Progress: Other P License Li iin E Europe Chugai Pharma Marketing obtained marketing license from two companies in Europe PharmaMar Plitidepsin / Aplidin®: Marketing rights
Slide 24: Down Syndrome (DS)
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline D Down S Syndrome d (DS) Karyotype for trisomy Down The most common chromosomal anomaly syndrome (trisomy of chromosome 21) with an incidence of one in 650 to 1,000 births1)
Slide 25: RG1662 (GABAAα5 receptor antagonist): Mode of Action
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline RG1662 (GABAAα5 5 receptor t antagonist): t i t) Mode M d off Action A ti RG1662: a small small-molecule molecule GABAAα5 receptor Structure of GABAA α5 receptor p and binding
Slide 26: RG7596 (Anti-CD79b ADC): Mode of Action
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline RG7596 (Anti (Anti-CD79b CD79b ADC) : Mode of Action RG7596 (polatuzumab vedotin) is an antibody-drug conjugate (ADC) MMAE created by Genentech utilizing ADC technology of Seat
Slide 27: Contacts: Corporate Communications Dept.
Contacts: Corporate Communications Dept. Media Relations Group Tel: +81 (0)3-3273-0881 Fax: +81 (0)3-3281-6607 e-mail: pr@chugai-pharm.co.jp K ki H Koki Harada, d Hiroshi Hi hi A Araki, ki Sachiyo S hi Yoshimura, Y hi Chi t Miyoshi Chisato Mi hi Investor Relations Group p Tel: +81 (0)3-3273-0554 Fax
Chugai Pharmaceutical — Q2 2014 Earnings Presentation on 6ix